Angelini Pharma Join Forces with Cureverse to Develop and Commercialize CV-01 for Brain Health
Shots:
- Angelini & Cureverse have signed an exclusive worldwide option agreement to develop & commercialize the latter’s CV-01 for brain health
- Angelini will lead CV-01’s development efforts and after an option period, can secure exclusive worldwide rights to develop & commercialize it (excl. South Korea, China, Hong Kong, Macau & Taiwan). Cureverse is entitled to receive an undisclosed upfront as well as up to $360M development & commercial milestones plus net-sales-based tiered royalties
- CV-01 is being developed by Cureverse under P-I study in South Korea for Alzheimer's disease. It works by activating Nrf2-regulated protective pathways and has potential disease-modifying abilities for brain health disorders such as epilepsy
Ref: Angelini & Cureverse | Image: Angelini & Cureverse
Related News:- Angelini Pharma Collaborated with JCR Pharmaceuticals to Develop and Commercialize Novel Biologic Therapies for Epilepsy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
